Company Overview
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +51.38% |
| 6 Months: | +5.50% |
| 3 Months: | +37.73% |
| 1 Month: | +21.86% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EPRX Eupraxia Pharmaceuticals Inc. PHARMA | 8.25 | -8.09 | $545.11M | 0.00% | -47.73% | -66.70% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 7.12M | 8.26M | 6.88M | 16.16M | 15.96M |
| Operating Income | - | -7.12M | -8.26M | -6.88M | -16.16M | -15.96M |
| EBITDA | - | -7.08M | -8.69M | -6.31M | -16.64M | -15.87M |
| Interest Expense | 137 | 0 | 0 | 0 | 0 | - |
| Pretax Income | - | -6.76M | -8.74M | -6.37M | -16.71M | -12.64M |
| Tax Provision | - | 2.79K | 5.58K | -623 | 11.34K | 13.90K |
| Net Income | - | -6.76M | -8.74M | -6.36M | -16.71M | -12.65M |
| Diluted EPS | - | -0.21 | -0.26 | -0.19 | - | -0.23 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 17.62M | 27.85M | 27.00M | 38.43M |
| Operating Income | - | -17.62M | -27.85M | -27.00M | -38.43M |
| EBITDA | - | -17.86M | -27.60M | -24.97M | -38.35M |
| Interest Expense | - | 982.86K | 1.17M | 603.57K | 0 |
| Pretax Income | - | -18.99M | -28.93M | -25.74M | -38.59M |
| Tax Provision | - | 0 | 36.42K | 1.80K | 19.09K |
| Net Income | - | -18.49M | -28.22M | -25.50M | -38.58M |
| Diluted EPS | - | -0.96 | -1.17 | -0.76 | -1.03 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 19.12M | 20.27M | 34.94M | 86.15M |
| Current Assets | - | 18.59M | 19.80M | 34.44M | 85.10M |
| Cash & Equivalents | - | 18.26M | 19.34M | 33.10M | 80.56M |
| Inventory | - | - | - | - | - |
| Receivables | - | 89.72K | 190.61K | 228.87K | 674.23K |
| Total Liabilities | - | 11.91M | 19.37M | 3.10M | 5.70M |
| Current Liabilities | - | 3.06M | 19.37M | 3.10M | 5.63M |
| Long Term Debt | 7.27M | 8.80M | - | - | - |
| Total Debt | - | 8.99M | 10.45M | 71.86K | 154.36K |
| Total Equity | - | 7.79M | 2.22M | 33.40M | 82.04M |
| Shares Outstanding | - | 21.59M | 27.28M | 35.64M | 51.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -14.40M | -20.75M | -29.99M | -28.55M |
| Investing Cash Flow | - | 9.83M | -73.38K | -75.16K | -588.95K |
| Financing Cash Flow | - | 10.80M | 21.08M | 45.78M | 76.06M |
| Capital Expenditure | - | -235.55K | -73.38K | -104.23K | -588.95K |
| Free Cash Flow | - | -14.63M | -20.82M | -30.10M | -29.14M |
| Net Change in Cash | - | 6.24M | 256.97K | 15.71M | 46.92M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -237.5% | -1,273.4% | -76.3% | -47.0% |
| ROCE % | - | -109.7% | -3,120.7% | -84.8% | -47.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Beutel, Goodman & Company Ltd | 5.58% | 3.63M | $31.13M |
| 2 | Affinity Asset Advisors, Llc | 2.54% | 1.65M | $14.16M |
| 3 | Balyasny Asset Management LP | 2.08% | 1.35M | $11.58M |
| 4 | Vivo Capital, LLC | 2.08% | 1.35M | $11.58M |
| 5 | Scotia Capital Inc. | 2.07% | 1.34M | $11.53M |
| 6 | Pfm Health Sciences, Lp | 1.86% | 1.21M | $10.39M |
| 7 | Great Point Partners LLC | 1.85% | 1.20M | $10.30M |
| 8 | Jupiter Topco LLC | 1.61% | 1.05M | $8.97M |
| 9 | Rubric Capital Management LP | 1.33% | 867.42K | $7.44M |
| 10 | Ikarian Capital, LLC | 1.25% | 809.74K | $6.95M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EPRX
No shareholder action is needed as Eupraxia shares move to Nasdaq’s highest tier. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSVBFU0kyU3JHeVhTSEc1M0QzLWhrQkNybkJzb2I0MGoySnhQLWdDdURUSW1HQnJzMWFwczYtY2U5b0NLQ0VERzRMeHBHYVpaTzNCUG44d0xHU1JsWUpSUUxNdUZUdm5CWF96TTlTalZUNndWQ0VEVS02dDQ3SmJQSmFvRnlaNEd6Ym9xTk…
EPRX Stock Jumps As Traders Eye Volatile Breakout - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxNeDNQRjBrWkFscjhtYzctd0lodVlxZDR5QTZvN080OU5HbkhnR1hnX0JFeWhQMG5mREZuQ2pKTzEtWFRINDhOQ1ZSczlCNjZFQlNVTUlWb0wzYmxFYVJ2ejdRODZlMVVJRnI0NW82TXh3UldmeXh2UG92OUZsSy1YMnpreHQ?oc=5" targ…
EPRX Jumps As Traders Focus On Cash Runway And Momentum - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOak5mNkRDTC1ZZ04wNW5yLU5BZzNvMDl3Wm9hQkpfR1E5VjhZZUdJaGRSYl9NQUlTWTFNUEZBLXBTVEdDZmNiX1lfb1JNVWM3TVdOQ29KcjQteTNrakpZdHV0YTVRZ29aTmJCaDNESnlmVlZucDZJdmF2LUVkTFBXbnQ1eFhCdw?oc=5" t…
Pharma Eupraxia (Nasdaq: EPRX) moves to Nasdaq's top tier - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPdzg3d1dYQlhfM09nTDhYaXdfQ2JmNXlOUnJ4VXVZaGxnT3RxX3NSR0wzV0FybjFhNGhDX2Rmd2g0QW05RXdRMnV0Yi1oODFteEtXMktDS3loUWN3WGc5MHdzRk14U2ZSZENFRjdzaENtZTJTWmdTQ3FOX043U3RmSG1PaVk0d3NWcTJhZG…
Discipline and Rules-Based Execution in EPRX Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNYk5vM3p2ang3SmEtaDJIbkU1YUxjZXIxSlJ3YkdTeTIyT3FyV2pVU1VsRzlYYWg0ZUFqNnhtenhSWWFPUlZCcFFyUjNwVXV2OG0zb05uZTg0MW5rNklyUU1QaDN1Y1cwWXdNczl6X1FTQzA5eEt1eGJZUFVQajdIeW0xdmJ0VGxpUmJhZW…
Why Did Eupraxia Pharmaceuticals (TSX:EPRX) Surge 12.36% on 4 September 2026? - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNnJOeUdFd085b0VYdXU4WG1GYWNMZGpabk1NbG5HYUxJV1Z3UTlsMXc0R3RYZ1pDaVA5TjlETENoT3hGT0tSelF0OTlabHB0c3Nhb1FoYVluQXFwWWo3QmFneVZwT2FwUjF1eTBxX2lFSWtseVNuMTVwbFltYXI5Q0xvY3QwVEhyTG5kX0…
EPRX — Frequently Asked Questions
What is the current share price of Eupraxia Pharmaceuticals Inc. (EPRX)?
As of 2026-09-19 21:16 PDT, Eupraxia Pharmaceuticals Inc. (EPRX) trades at $8.25 on NasdaqGS. Its 52-week range is $5.05 to $9.07.
What is the market capitalisation of EPRX?
Eupraxia Pharmaceuticals Inc. (EPRX) has a market capitalisation of $545.11M on NasdaqGS.
What is the P/E ratio of EPRX?
EPRX trades at a trailing price-to-earnings (P/E) ratio of -8.09. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.20.
What is the return on equity (ROE) of EPRX?
EPRX has a return on equity (ROE) of -66.70%. Its return on capital employed (ROCE) is -47.73%.
Is EPRX a good stock to buy?
This page provides a data-driven analysis of Eupraxia Pharmaceuticals Inc. (EPRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.